Specific treatment in the acute phase after @entity1779 is still not available. Corticosteroids and early surgical evacuation have been proven to be ineffective. In the initial 3 hours after a @entity1779 , the haematoma volume increases in one-third of all @entity1 . Arresting this enlargement may be an effective strategy to improve outcome. Recombinant activated factor VII (rFVIIa) is used to treat @entity548 in @entity1 with @entity447 and has also been reported to reduce @entity548 in @entity1 without @entity1003 . In a recently published phase-II trial totalling 399 @entity1 given placebo or one of three doses of rFVIIa, treatment with rFVIIa reduced haematoma volume 24 hours after administration. Treatment with rFVIIa was also superior to placebo for several secondary endpoints, including @entity204 , handicap and @entity51 . However, more @entity1031 , including @entity583 and @entity64 , occurred in the groups given rFVIIa. A new trial, with @entity204 or dependency as the primary outcome, has recently been started. The results are expected early in 2007.

[Acute treatment with recombinant factor VII is probably indicated for XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['ischaemic stroke'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['coagulopathy'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficits'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic complications'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['cerebral haemorrhage']
@entity1779 :: (MESH:D002543,Disease) :: ['intracerebral haematoma']
